🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆
Updated 13 Sep 2026 · EMA CTIS official data

Clinical Trials in Denmark

← All EU trials

The most recently authorised clinical trials across the European Union - drawn live from the European Medicines Agency's Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation. Searchable by country, phase, sponsor and condition.

80
Recent authorisations
34
Phase III trials
Denmark
Selected country
Showing 80 trials
Phase IV Anesthesia and Analgesia Authorised 08/09/2026

POISON – Perioperative Safety and Effective Opioid Dosing in Chronic Opioid Use – a Randomized Clinical Study

Opioid dependent chronic pain
Region Hovedstaden
318 participants planned
Denmark
2026-526719-13-00 on CTIS ↗
Phase II Male Urogenital Diseases Authorised 08/09/2026

SemenGlutide: A randomized double-blinded, placebo-controlled, single-center, clinical trial comparing the effects of s.c. Semaglutide 2.4 mg once-weekly versus placebo on sperm concentration in overweight infertile men

Infertility, overweight
Region Hovedstaden
150 participants planned
Denmark
2026-527538-29-00 on CTIS ↗
Phase II Hormonal diseases Authorised 08/09/2026

Effects of semaglutide as add-on therapy to sulfonylurea on plasma glucose in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SEMA)

Maturity-onset diabetes of the young type 3 (HNF1A-MODY), Maturity-onset diabetes of the young type 1 (HNF4A-MODY)
Steno Diabetes Center Copenhagen
54 participants planned
Denmark
2025-523414-89-00 on CTIS ↗
Phase III Neoplasms Authorised 07/09/2026

Zoledronic acid as prophylaxis against glucocorticoid-induced osteoporosis in lymphoma

Large B-cell lymphomas, transformations of indolent B-cell lymphomas, mantle cell lymphoma, follicular lymphoma, Burkitt lymphoma and T-cell lymphomas (The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms), Glucocorticoid induced osteoporosis
Region Nordjylland
132 participants planned
Denmark
2026-527220-27-00 on CTIS ↗
Phase I Neoplasms Authorised 07/09/2026

A Study of RO7806767 as Single Agent and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Advanced Solid Tumors
F. Hoffmann-La Roche AG
99 participants planned
Spain · Hungary · Italy · Belgium · Denmark · France
2026-525215-13-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 02/09/2026

Reduced-dose versus full-dose systemic thrombolysis for high-risk pulmonary embolism: a multicentre, randomised, open-label, blinded-endpoint trial

Pulmonary embolism
Vaestra Goetalandsregionen, University Of Gothenburg
280 participants planned
Denmark · Sweden · Norway
2024-515904-37-00 on CTIS ↗
Phase III Immune System Diseases Authorised 02/09/2026

A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy

Immune system diseases
Sanofi-Aventis Recherche & Developpement
338 participants planned
Belgium · Czechia · Hungary · Sweden · Lithuania · Croatia · Netherlands · Slovakia · Poland · Austria · Norway · France · Italy · Bulgaria · Spain · Germany · Romania · Slovenia · Estonia · Portugal · Greece · Denmark
2026-525913-30-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 02/09/2026

Antibiotikapenetration og vævsrespons ved infektion og rekonstruktiv kirurgi i hoved-hals regionen

Treatment and prevention of post operative infections
Region Midtjylland
16 participants planned
Denmark
2026-526995-22-00 on CTIS ↗
Phase II Eye Diseases Authorised 01/09/2026

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompe' Farmaceutici S.p.A.
171 participants planned
Denmark · Italy · Germany · Hungary · Netherlands · Spain · Belgium · France · Portugal
2025-524748-37-00 on CTIS ↗
Phase III Neoplasms Authorised 01/09/2026

A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5).

Newly Diagnosed Multiple Myeloma
AstraZeneca AB
234 participants planned
Poland · Italy · Denmark · France · Sweden · Germany · Spain
2025-524014-29-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 31/08/2026

HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL)
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
276 participants planned
Czechia · Denmark · Croatia · Spain · Sweden · Finland · Portugal · Ireland · Netherlands · Belgium · Norway
2025-524230-25-00 on CTIS ↗
Phase II Immune System Diseases Authorised 31/08/2026

Targeting IL-13 in Bullous Pemphigoid: An Investigator-Initiated, Prospective, Multicenter, Proof-of-Concept, Open-Label Pilot Study of Lebrikizumab

Bullous pemphigoid
Region Midtjylland, Region Sjaelland
25 participants planned
Denmark
2026-525685-22-00 on CTIS ↗
Phase II Diagnosis Authorised 28/08/2026

Paediatric sarcoma, hybrid imaging & FAPI – Raising the diagnostic standard for paediatric sarcoma patients combining novel radiotracer FAPI and whole-body PET/MRI

Paediatric sarcoma
Rigshospitalet
40 participants planned
Denmark
2025-524874-41-00 on CTIS ↗
Phase IV Pathological Conditions, Signs and Symptoms Authorised 27/08/2026

S-KETamine vs. propofol for prehospital sedation of patients with severe Acute Brain Injury: The KETABI randomised trial

traumatic brain injury, subarachnoid haemorrhage, intracerebral haemorrhage
Region Hovedstaden
284 participants planned
Denmark
2026-525588-41-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 26/08/2026

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Contineum Therapeutics Inc.
156 participants planned
Italy · Belgium · Denmark · Austria · Greece · Germany · France · Netherlands · Portugal · Poland · Spain
2025-521901-42-00 on CTIS ↗
Phase II Neoplasms Authorised 26/08/2026

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

Gastrointestinal Cancers
Genmab A/S
67 participants planned
Italy · Belgium · France · Spain · Denmark · Netherlands · Germany
2025-524130-26-00 on CTIS ↗
Phase IV Bacterial Infections and Mycoses Authorised 25/08/2026

Piperacillin/tazobactam or ampicillin and gentamicin for empirical treatment of community acquired infection: A randomised clinical trial (PAGER)

Urosepsis, Infection of unknown origin, Pyelonephritis, Cystitis, Urinary tract infection, Pneumonia, Sepsis
Region Hovedstaden
2162 participants planned
Denmark
2026-526131-20-00 on CTIS ↗
Phase III Neoplasms Authorised 24/08/2026

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)

Pancreatic Adenocarcinoma
Revolution Medicines Inc.
281 participants planned
Sweden · Spain · France · Poland · Italy · Norway · Belgium · Germany · Czechia · Austria · Netherlands · Denmark
2025-524928-21-00 on CTIS ↗
Phase IV Skin and Connective Tissue Diseases Authorised 24/08/2026

Adalimumab Treatment for Patients with Hidradenitis Suppurativa at high risk of Progressing to Severe Disease: An Unblinded Randomized, Controlled Trial

Hidradenitis suppurativa
Gentofte Hospital
100 participants planned
Denmark
2025-522505-37-00 on CTIS ↗
Phase II Bacterial Infections and Mycoses Authorised 21/08/2026

Èn dosis intravenøs penicillin som tillæg til peroral penicillin i behandlingen af akut tonsillitis, peritonsillær phlegmone og peritonsillær absces – et randomiseret, dobbeltblindet, placebo-kontrolleret studie

Tonsillitis
Region Midtjylland
154 participants planned
Denmark
2026-526903-31-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 20/08/2026

An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin Amyloidosis
Eidos Therapeutics Inc.
50 participants planned
Spain · Denmark
2026-526068-19-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 18/08/2026

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)

Elevated lipoprotein(a)
Merck Sharp & Dohme LLC
295 participants planned
Netherlands · Denmark · Germany · Spain
2025-525102-38-00 on CTIS ↗
Phase III Neoplasms Authorised 17/08/2026

Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)

Small-cell lung cancer, limited stage
Norges Teknisk-Naturvitenskapelige Universitet NTNU
426 participants planned
Denmark · Finland · Estonia · Germany · Lithuania · Sweden · Norway · Netherlands
2026-525513-31-00 on CTIS ↗
Phase II Neoplasms Authorised 14/08/2026

[⁶⁸Ga]Ga-HKG301 PET/CT for staging and restaging patients with primary breast cancer: a phase II study (FAPILOUS)

Primary breast cancer
Odense University Hospital
65 participants planned
Denmark
2025-521324-29-00 on CTIS ↗
Phase II Immune System Diseases Authorised 10/08/2026

A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA) (Breakfree-AiCE)

Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA)
Celgene Corp.
3 participants planned
Germany · Denmark
2025-524993-41-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 10/08/2026

Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity

Overweight and obesity
Novo Nordisk A/S
315 participants planned
Netherlands · Belgium · Greece · Poland · Spain · Denmark · France · Bulgaria · Sweden
2025-524626-18-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 10/08/2026

The RHINOME study

Severe asthma
Region Hovedstaden
72 participants planned
Denmark
2026-527032-14-00 on CTIS ↗
Phase II Therapeutics Authorised 10/08/2026

An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma

Cutaneous T-cell lymphoma (CTCL) Mycosis fungoides
Region Midtjylland
15 participants planned
Denmark
2025-523472-23-01 on CTIS ↗
Phase III Hormonal diseases Authorised 07/08/2026

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs

Graves' Disease (GD)
Argenx
145 participants planned
Italy · Czechia · Spain · Denmark · Belgium · Romania · Latvia · France · Germany · Greece · Sweden · Poland · Lithuania · Bulgaria
2025-523333-26-00 on CTIS ↗
Phase IV Virus Diseases Authorised 07/08/2026

A Phase 4, Pragmatic, Randomized Trial to Evaluate the Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years (DAN-COMBO)

SARS-CoV-2 infection, Influenza infection
Gentofte Hospital, Moderna Inc.
410000 participants planned
Denmark · Spain
2026-526720-49-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 04/08/2026

ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment

Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES), Asthma
AstraZeneca AB
94 participants planned
Denmark · Belgium · France · Italy · Netherlands · Austria · Poland
2025-523307-29-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 04/08/2026

A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)

Idiopathic Pulmonary Fibrosis
AstraZeneca AB
139 participants planned
Poland · Hungary · Netherlands · Germany · Spain · Greece · Bulgaria · Italy · France · Denmark
2025-525016-41-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 03/08/2026

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron compared with Placebo in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)

type 2 diabetes mellitus
AstraZeneca AB
183 participants planned
Germany · Bulgaria · Spain · Denmark
2025-523940-12-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 03/08/2026

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared with Elecoglipron Alone and Dapagliflozin Alone, in Adults with Type 2 Diabetes Mellitus (Eluminate-5)

type 2 diabetes mellitus
AstraZeneca AB
360 participants planned
Slovakia · Poland · Czechia · Germany · Hungary · Greece · Denmark
2025-523941-81-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 03/08/2026

A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)

Systemic sclerosis
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
179 participants planned
Denmark · Hungary · Sweden · Netherlands · Germany · Belgium · France · Greece · Norway · Finland · Czechia · Portugal · Bulgaria · Spain · Austria · Romania · Croatia · Poland · Estonia · Italy · Lithuania
2025-523884-39-00 on CTIS ↗
Phase III Immune System Diseases Authorised 03/08/2026

A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis
Janssen Cilag International
302 participants planned
France · Bulgaria · Romania · Slovakia · Norway · Denmark · Greece · Italy · Austria · Poland · Netherlands · Czechia · Germany · Belgium · Spain · Hungary · Portugal
2026-525923-26-00 on CTIS ↗
Phase II Therapeutics Authorised 01/08/2026

Botulinum toxin A in the Treatment of Chronic Postsurgical Pain in Lung Cancer Patients: A feasibility study

Chronic postsurgical pain (CPSP)
Aalborg University Hospital
15 participants planned
Denmark
2026-525669-33-00 on CTIS ↗
Phase II Mental Disorders Authorised 01/08/2026

The Danish Anorexia Nervosa Psilocybin RCT (DANP-RCT). A Randomised, Active-Placebo-Controlled, Triple-blind, Superiority Study of Psilocybin-Assisted Acceptance and Commitment Therapy (ACT) in the Treatment of Treatment-resistant Anorexia Nervosa.

Anorexia nervosa
Slagelse Hospital
62 participants planned
Denmark
2025-524939-39-02 on CTIS ↗
Phase I/II Nervous System Diseases Authorised 30/07/2026

A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3

Spinocerebellar ataxia type 3
Institut De Recherches Internationales Servier IRIS
50 participants planned
France · Denmark · Spain · Portugal
2025-525111-17-00 on CTIS ↗
Phase III Neoplasms Authorised 29/07/2026

A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1)

Follicular Lymphoma
AstraZeneca AB
15 participants planned
Denmark
2023-510098-33-01 on CTIS ↗
Phase I Neoplasms Authorised 27/07/2026

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination with Bevacizumab in Adult Participants with Ovarian Cancer

Ovarian Cancer
AbbVie Deutschland GmbH & Co. KG
44 participants planned
Portugal · Denmark · Spain · France
2025-522209-40-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 24/07/2026

A randomised active-controlled trial to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation

non-valvular atrial fibrillation
Ribocure Pharmaceuticals AB
150 participants planned
Norway · Denmark · Poland · Sweden
2026-525417-31-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 24/07/2026

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)

Chronic kidney disease (CKD) in adults, with specified ranges of eGFR and albuminuria (UACR), irrespective of T2DM status; background SGLT2i dapagliflozin 10 mg as GDMT.
AstraZeneca AB
1600 participants planned
Czechia · Italy · Hungary · Romania · Bulgaria · Sweden · Denmark · Poland · Spain · Norway · Finland · Greece · France · Germany
2025-523994-41-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 21/07/2026

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis
Ipsen Bioscience Inc.
127 participants planned
Spain · Sweden · Germany · Romania · Finland · Portugal · Austria · Italy · Denmark · Czechia · France · Netherlands · Poland · Belgium · Norway
2026-525242-29-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 20/07/2026

A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease

Huntington’s Disease
Novartis Pharma AG
368 participants planned
Norway · Poland · Spain · Sweden · Bulgaria · Netherlands · Finland · Portugal · Austria · Italy · Greece · Ireland · Czechia · France · Romania · Belgium · Germany · Denmark · Slovakia · Hungary
2025-522227-99-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 20/07/2026

Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Subjects (age 12 to <18 years) with Homozygous Familial Hypercholesterolemia (SPRUCE)

Homozygous Familial Hypercholesterolemia (HoFH)
Arrowhead Pharmaceuticals Inc.
9 participants planned
Netherlands · Denmark · Norway · Sweden · Poland
2025-523662-24-00 on CTIS ↗
Phase III Neoplasms Authorised 14/07/2026

A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Metastatic colorectal cancer
Merck Healthcare KGaA
323 participants planned
Belgium · Germany · France · Denmark · Poland · Spain · Netherlands · Italy · Austria
2025-524648-37-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 14/07/2026

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma

Metastatic Pancreatic Adenocarcinoma
Revolution Medicines Inc.
337 participants planned
Poland · Belgium · Norway · Sweden · Austria · Germany · Denmark · Netherlands · France · Italy · Spain
2025-525088-34-00 on CTIS ↗
Phase IV Female Urogenital Diseases and Pregnancy Complications Authorised 14/07/2026

Efficacy of oral bicarbonate versus placebo on the risk of assisted delivery in nulliparous women with prolonged labour (ProLabour): protocol fora randomized controlled trial

Prolonged labour
Region Hovedstaden
1520 participants planned
Denmark
2026-525682-45-00 on CTIS ↗
Phase II Immune System Diseases Authorised 13/07/2026

Inducing durable immunological control of HIV-1 through administration of long-acting broadly neutralizing antibodies and low-dose anti-PD-1 – a randomized, double-blinded, placebo-controlled trial (the IDUNN trial)

HIV-1 disease
Region Midtjylland
60 participants planned
Sweden · Norway · Denmark · Iceland
2025-523725-17-00 on CTIS ↗
Phase I Neoplasms Authorised 13/07/2026

A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

Relapsed or Refractory acute myeloid leukemia, Relapsed or Refractory chronic lymphocytic leukemia, Relapsed or Refractory higher-risk myelodysplastic syndromes, Relapsed or Refractory small lymphocytic lymphoma
Janssen Cilag International
175 participants planned
France · Spain · Germany · Denmark · Belgium
2026-525234-39-00 on CTIS ↗
Phase I/II Neoplasms Authorised 10/07/2026

EXUROC Bladder Target - A phase Ib/ll study to determine the safety, tolerability, and efficacy of LP-184 treatment in patients with advanced/metastatic urothelial carcinoma

Oncology
Region Hovedstaden
39 participants planned
Denmark
2026-525808-94-00 on CTIS ↗
Phase III Neoplasms Authorised 08/07/2026

Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

Osteosarcoma
Institut Gustave Roussy
508 participants planned
Sweden · Poland · Denmark · Finland · Netherlands · Italy · France · Spain
2023-505575-69-01 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 07/07/2026

A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B)

Fibrosing interstitial lung disease
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
20 participants planned
Belgium · Greece · Germany · France · Finland · Spain · Czechia · Poland · Italy · Netherlands · Denmark · Portugal
2025-523369-32-00 on CTIS ↗
Phase III Neoplasms Authorised 07/07/2026

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Multiple Myeloma who Have Received One to Three Prior Lines of Therapy

Multiple Myeloma
F. Hoffmann-La Roche AG
133 participants planned
France · Germany · Italy · Greece · Denmark · Czechia · Spain · Poland
2025-524028-23-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 06/07/2026

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement
613 participants planned
Denmark · Sweden · Poland · Estonia · Portugal · Latvia · Spain · Hungary · Germany · Finland · Italy · Belgium · France
2024-518016-39-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 06/07/2026

Efficacy, Safety, and Patient Satisfaction of Patient-Controlled Remimazolam Sedation in Outpatient Colonoscopy: A randomized controlled trial.

The trial will study sedation related to colonoscopy, therefore the trial is not concerned with the underlaying medical condition leading to the colonoscopy.
Region Hovedstaden
1 participants planned
Denmark
2026-525809-13-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 06/07/2026

The RELEASE Trial: Reconsidering Long-Term Aspirin in the Elderly in Secondary Prevention of Cardiovascular Disease

Ischemic heart disease/Chronic coronary syndrome (Myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting)
Odense University Hospital
7000 participants planned
Denmark
2026-525442-30-00 on CTIS ↗
Phase IV Musculoskeletal Diseases Authorised 06/07/2026

Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference

Rheumatoid arthritis
Aalborg University Hospital, Aalborg University Hospital
180 participants planned
Denmark
2026-525221-21-01 on CTIS ↗
Phase II Mental Disorders Authorised 03/07/2026

The Acute and Long-term Impact of Support in Psilocybin Therapy for Depression: The Psilocybin Setting Trial (PSISET)

Depression
Kobenhavns Universitet, Koebenhavns Universitet
180 participants planned
Denmark
2025-522961-31-01 on CTIS ↗
Phase I Female Urogenital Diseases and Pregnancy Complications Authorised 03/07/2026

Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial - The CALCIFER Trial

Bladder cancer, Bladder tumors, Urothelial cancer, Urothelial tumors
Region Sjaelland
20 participants planned
Denmark
2026-526388-39-00 on CTIS ↗
Phase I/II Nervous System Diseases Authorised 01/07/2026

The headache- and migraine-inducing effects of apremilast in women with migraine without aura

Migraine without aura
Syddansk Universitet (University of Southern Denmark)
14 participants planned
Denmark
2026-525987-16-00 on CTIS ↗
Phase III Neoplasms Authorised 01/07/2026

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
Genmab A/S
257 participants planned
Finland · Belgium · Hungary · France · Denmark · Austria · Germany · Italy · Spain · Czechia · Norway · Poland
2025-522167-15-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 30/06/2026

A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Pulmonary Hypertension Associated with Interstitial Lung Disease
Insmed Inc.
165 participants planned
Greece · France · Italy · Belgium · Denmark · Germany · Poland · Czechia · Portugal · Austria · Spain · Romania
2025-521769-29-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 30/06/2026

A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma

Participants with relapsed HRNB and participants with HRNB refractory to treatment The clinical trial will recruit participants aged ≥18 months to <18 years, and therefore all participants will be minors at the time of consent.
Renaissance Pharma Limited
111 participants planned
France · Spain · Denmark · Ireland · Germany
2025-524397-42-00 on CTIS ↗
Phase IV Mental Disorders Authorised 29/06/2026

Unprescribing the Pill to Reassess Symptom and Cognitive Recovery in Depression (UNPRESCRIB-D)

Major Depressive Disorder
Region Hovedstaden
106 participants planned
Denmark
2026-526314-90-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 28/06/2026

Self-Assessment Method for Statin side-effects Or Nocebo 2

Cardiovascular diseases
Copenhagen University Hospital, Region Hovedstaden
160 participants planned
Denmark
2025-524955-30-01 on CTIS ↗
Phase IV Hemic and Lymphatic Diseases Authorised 25/06/2026

A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol

Haematological diseases; any disorder that primarily affects the blood, bone marrow, the lymphatic system and/or blood-forming organs.
Region Hovedstaden
200 participants planned
Denmark
2026-525658-13-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 25/06/2026

Evaluating the effect of inhaled levodopa (Inbrija®) for early morning off in Parkinson’s disease

parkinson's disease
Region Hovedstaden
22 participants planned
Denmark
2026-526465-18-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 23/06/2026

A Phase IIb, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50).

Heriditary spastic paraplegia (SPG50)
Rigshospitalet, Elpida Therapeutics SPC
2 participants planned
Denmark
2025-524481-15-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 22/06/2026

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Non-active Secondary Progressive Multiple Sclerosis (SPMS)
Zenas Biopharma (USA) LLC
486 participants planned
Germany · Bulgaria · Netherlands · Sweden · Portugal · Croatia · Italy · Austria · Spain · Poland · France · Denmark · Hungary · Romania · Estonia · Slovakia · Belgium · Czechia · Norway · Lithuania · Greece
2025-524322-18-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 22/06/2026

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)

Osteogenesis Imperfecta
Angitia Inc. Ltd.
40 participants planned
Netherlands · France · Denmark
2025-522951-24-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 22/06/2026

A Phase 2, Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of LTG-321 in Patients with Osteoarthritis of the Knee

Osteoarthritis of the knee
Latigo Biotherapeutics Inc.
180 participants planned
Denmark
2026-525966-22-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 17/06/2026

A phase 1 first-in-human study of a phenylalanine-binding polymer (phelimin) in healthy volunteers and adult, classical PKU patients

Phenylketonuria
Mipsalus ApS
7 participants planned
Denmark
2024-519121-38-01 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 17/06/2026

IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis

Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis
Bristol-Myers Squibb Services Unlimited Company
318 participants planned
Finland · Portugal · Hungary · Ireland · Poland · Greece · France · Belgium · Denmark · Italy · Spain · Netherlands · Austria · Germany
2025-522373-10-00 on CTIS ↗
Phase I Neoplasms Authorised 16/06/2026

A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Hematological malignancies, Advanced solid tumors
Incyte Corp.
150 participants planned
Italy · Belgium · Denmark
2025-523130-11-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 15/06/2026

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)

Limb Girdle Muscular Dystrophy (LGMD) Type 2I
ML Bio Solutions Inc.
35 participants planned
Germany · Denmark · Netherlands · Italy · Norway
2025-524371-23-00 on CTIS ↗
Phase II Neoplasms Authorised 15/06/2026

A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Participants with RRMM, who Received 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy

Multiple myeloma (RRMM)
Odense University Hospital
50 participants planned
Finland · Denmark · Estonia · Norway
2025-522114-23-00 on CTIS ↗
Phase III Neoplasms Authorised 12/06/2026

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

​Relapsed/refractory B-cell Acute Lymphoblastic Leukemia​
Merck Sharp & Dohme LLC
109 participants planned
Greece · Netherlands · Sweden · France · Italy · Spain · Denmark
2025-522267-15-00 on CTIS ↗
Phase IV Musculoskeletal Diseases Authorised 12/06/2026

BEAT Fatigue – Benefit of Elevated Administration of Thiamine for Fatigue in Rheumatoid Arthritis: A randomized, double-blind, placebo-controlled trial

Fatigue in rheumatoid arthritis patients
Odense University Hospital
150 participants planned
Denmark
2024-519268-41-00 on CTIS ↗
No trials match your search.
Cite this page

Priya Life Science (2026). EU Clinical Trials Tracker. Available at: https://priyalifescience.com/clinical-trials-europe/country/denmark (Accessed: 13 September 2026).

Embed this data ↗

Source: Clinical Trials Information System (CTIS), European Medicines Agency - trials authorised under the EU Clinical Trials Regulation (Regulation 536/2014), showing the most recent EU authorisation decisions, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See our Ireland Clinical Trials Tracker. For approved medicines, see the EMA Approvals Tracker. See who's running these trials in our Company Directory, or compare pay across these markets in the EU Salary Guide.